Author Correction: PRL3-zumab as an immunotherapy to inhibit tumors expressing PRL3 oncoprotein (Nature Communications, (2019), 10, 1, (2484), 10.1038/s41467-019-10127-x)

Min Thura; Abdul Qader Al-Aidaroos; Abhishek Gupta; Cheng Ean Chee; Soo Chin Lee; Kam Man Hui; Jie Li; Yeoh Khay Guan; Wei Peng Yong; Jimmy So; Wee Joo Chng; Chin Hin Ng; Jianbiao Zhou; Ling Zhi Wang; John Shyi Peng Yuen; Henry Sun Sien Ho; Sim Mei Yi; Edmund Chiong; Su Pin Choo; Joanne Ngeow; Matthew Chau Hsien Ng; Clarinda Chua; Eugene Shen Ann Yeo; Iain Bee Huat Tan; Joel Xuan En Sng; Nicholas Yan Zhi Tan; Jean Paul Thiery; Boon Cher Goh; Qi Zeng

doi:10.1038/s41467-021-26548-6

Author Correction: PRL3-zumab as an immunotherapy to inhibit tumors expressing PRL3 oncoprotein (Nature Communications, (2019), 10, 1, (2484), 10.1038/s41467-019-10127-x)

Min Thura, Abdul Qader Al-Aidaroos, Abhishek Gupta, Cheng Ean Chee, Soo Chin Lee, Kam Man Hui, Jie Li, Yeoh Khay Guan, Wei Peng Yong, Jimmy So, Wee Joo Chng, Chin Hin Ng, Jianbiao Zhou, Ling Zhi Wang, John Shyi Peng Yuen, Henry Sun Sien Ho, Sim Mei Yi, Edmund Chiong, Su Pin Choo, Joanne NgeowMatthew Chau Hsien Ng, Clarinda Chua, Eugene Shen Ann Yeo, Iain Bee Huat Tan, Joel Xuan En Sng, Nicholas Yan Zhi Tan, Jean Paul Thiery, Boon Cher Goh, Qi Zeng^*

^*Corresponding author for this work

Research output: Contribution to journal › Comment/debate › peer-review

1 Citation (Scopus)

Abstract

In this article the funding from ‘Open Fund-Individual Research Grant (OF-IRG), National Medical Research Council (NMRC) Singapore with the project ID of NMRC/OFIRG/0053/2017’ was omitted.

Original language	English
Article number	6431
Journal	Nature Communications
Volume	12
Issue number	1
DOIs	https://doi.org/10.1038/s41467-021-26548-6
Publication status	Published - Dec 1 2021
Externally published	Yes

Bibliographical note

Publisher Copyright:
© The Author(s) 2021.

ASJC Scopus Subject Areas

General Chemistry
General Biochemistry,Genetics and Molecular Biology
General Physics and Astronomy

Access to Document

10.1038/s41467-021-26548-6

Cite this

Thura, M., Al-Aidaroos, A. Q., Gupta, A., Chee, C. E., Lee, S. C., Hui, K. M., Li, J., Guan, Y. K., Yong, W. P., So, J., Chng, W. J., Ng, C. H., Zhou, J., Wang, L. Z., Yuen, J. S. P., Ho, H. S. S., Yi, S. M., Chiong, E., Choo, S. P., ... Zeng, Q. (2021). Author Correction: PRL3-zumab as an immunotherapy to inhibit tumors expressing PRL3 oncoprotein (Nature Communications, (2019), 10, 1, (2484), 10.1038/s41467-019-10127-x). Nature Communications, 12(1), Article 6431. https://doi.org/10.1038/s41467-021-26548-6

@article{82db71b1c1bb4c1eb6f65169275988f6,

title = "Author Correction: PRL3-zumab as an immunotherapy to inhibit tumors expressing PRL3 oncoprotein (Nature Communications, (2019), 10, 1, (2484), 10.1038/s41467-019-10127-x)",

abstract = "In this article the funding from {\textquoteleft}Open Fund-Individual Research Grant (OF-IRG), National Medical Research Council (NMRC) Singapore with the project ID of NMRC/OFIRG/0053/2017{\textquoteright} was omitted.",

author = "Min Thura and Al-Aidaroos, \{Abdul Qader\} and Abhishek Gupta and Chee, \{Cheng Ean\} and Lee, \{Soo Chin\} and Hui, \{Kam Man\} and Jie Li and Guan, \{Yeoh Khay\} and Yong, \{Wei Peng\} and Jimmy So and Chng, \{Wee Joo\} and Ng, \{Chin Hin\} and Jianbiao Zhou and Wang, \{Ling Zhi\} and Yuen, \{John Shyi Peng\} and Ho, \{Henry Sun Sien\} and Yi, \{Sim Mei\} and Edmund Chiong and Choo, \{Su Pin\} and Joanne Ngeow and Ng, \{Matthew Chau Hsien\} and Clarinda Chua and Yeo, \{Eugene Shen Ann\} and Tan, \{Iain Bee Huat\} and Sng, \{Joel Xuan En\} and Tan, \{Nicholas Yan Zhi\} and Thiery, \{Jean Paul\} and Goh, \{Boon Cher\} and Qi Zeng",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2021.",

year = "2021",

month = dec,

day = "1",

doi = "10.1038/s41467-021-26548-6",

language = "English",

volume = "12",

journal = "Nature Communications",

issn = "2041-1723",

publisher = "Nature Publishing Group",

number = "1",

}

Thura, M, Al-Aidaroos, AQ, Gupta, A, Chee, CE, Lee, SC, Hui, KM, Li, J, Guan, YK, Yong, WP, So, J, Chng, WJ, Ng, CH, Zhou, J, Wang, LZ, Yuen, JSP, Ho, HSS, Yi, SM, Chiong, E, Choo, SP, Ngeow, J, Ng, MCH, Chua, C, Yeo, ESA, Tan, IBH, Sng, JXE, Tan, NYZ, Thiery, JP, Goh, BC & Zeng, Q 2021, 'Author Correction: PRL3-zumab as an immunotherapy to inhibit tumors expressing PRL3 oncoprotein (Nature Communications, (2019), 10, 1, (2484), 10.1038/s41467-019-10127-x)', Nature Communications, vol. 12, no. 1, 6431. https://doi.org/10.1038/s41467-021-26548-6

Author Correction: PRL3-zumab as an immunotherapy to inhibit tumors expressing PRL3 oncoprotein (Nature Communications, (2019), 10, 1, (2484), 10.1038/s41467-019-10127-x). / Thura, Min; Al-Aidaroos, Abdul Qader; Gupta, Abhishek et al.
In: Nature Communications, Vol. 12, No. 1, 6431, 01.12.2021.

Research output: Contribution to journal › Comment/debate › peer-review

TY - JOUR

T1 - Author Correction

T2 - PRL3-zumab as an immunotherapy to inhibit tumors expressing PRL3 oncoprotein (Nature Communications, (2019), 10, 1, (2484), 10.1038/s41467-019-10127-x)

AU - Thura, Min

AU - Al-Aidaroos, Abdul Qader

AU - Gupta, Abhishek

AU - Chee, Cheng Ean

AU - Lee, Soo Chin

AU - Hui, Kam Man

AU - Li, Jie

AU - Guan, Yeoh Khay

AU - Yong, Wei Peng

AU - So, Jimmy

AU - Chng, Wee Joo

AU - Ng, Chin Hin

AU - Zhou, Jianbiao

AU - Wang, Ling Zhi

AU - Yuen, John Shyi Peng

AU - Ho, Henry Sun Sien

AU - Yi, Sim Mei

AU - Chiong, Edmund

AU - Choo, Su Pin

AU - Ngeow, Joanne

AU - Ng, Matthew Chau Hsien

AU - Chua, Clarinda

AU - Yeo, Eugene Shen Ann

AU - Tan, Iain Bee Huat

AU - Sng, Joel Xuan En

AU - Tan, Nicholas Yan Zhi

AU - Thiery, Jean Paul

AU - Goh, Boon Cher

AU - Zeng, Qi

PY - 2021/12/1

Y1 - 2021/12/1

N2 - In this article the funding from ‘Open Fund-Individual Research Grant (OF-IRG), National Medical Research Council (NMRC) Singapore with the project ID of NMRC/OFIRG/0053/2017’ was omitted.

AB - In this article the funding from ‘Open Fund-Individual Research Grant (OF-IRG), National Medical Research Council (NMRC) Singapore with the project ID of NMRC/OFIRG/0053/2017’ was omitted.

UR - http://www.scopus.com/inward/record.url?scp=85118426674&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85118426674&partnerID=8YFLogxK

U2 - 10.1038/s41467-021-26548-6

DO - 10.1038/s41467-021-26548-6

M3 - Comment/debate

C2 - 34728638

AN - SCOPUS:85118426674

SN - 2041-1723

VL - 12

JO - Nature Communications

JF - Nature Communications

IS - 1

M1 - 6431

ER -

Author Correction: PRL3-zumab as an immunotherapy to inhibit tumors expressing PRL3 oncoprotein (Nature Communications, (2019), 10, 1, (2484), 10.1038/s41467-019-10127-x)

Abstract

Bibliographical note

ASJC Scopus Subject Areas

Access to Document

Other files and links

Fingerprint

Cite this